Patents Assigned to Viacyte, Inc.
  • Patent number: 12576142
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Grant
    Filed: September 21, 2023
    Date of Patent: March 17, 2026
    Assignee: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Publication number: 20260000828
    Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively scaling a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
    Type: Application
    Filed: July 17, 2025
    Publication date: January 1, 2026
    Applicant: ViaCyte, Inc.
    Inventors: Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
  • Publication number: 20250366970
    Abstract: Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.
    Type: Application
    Filed: March 26, 2025
    Publication date: December 4, 2025
    Applicant: ViaCyte, Inc.
    Inventors: Vincent So, Laura Martinson, Chad Green, Michael Scott, Mario Zamarripa
  • Publication number: 20250325360
    Abstract: A biocompatible membrane composite including a cell impermeable layer and a mitigation layer is provided. The cell impermeable layer is impervious to vascular ingrowth and prevents cellular contact from the host. Additionally, the mitigation layer includes solid features. In at least one embodiment, mitigation layer has therein bonded solid features. In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded or otherwise connected to each other to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned external to or within the biocompatible membrane composite to provide support to and prevent distortion. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.
    Type: Application
    Filed: April 25, 2025
    Publication date: October 23, 2025
    Applicants: W. L. Gore & Associates, Inc., Viacyte, Inc.
    Inventors: Timothy M. Bruhn, Kevin D'Amour, Christopher Folk, Craig McGreevy, Laura Martinson, Scott A. Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Joseph Kakkassery
  • Patent number: 12383670
    Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: August 12, 2025
    Assignee: ViaCyte, Inc.
    Inventors: Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
  • Patent number: 12310830
    Abstract: A biocompatible membrane composite including a cell impermeable layer and a mitigation layer is provided. The cell impermeable layer is impervious to vascular ingrowth and prevents cellular contact from the host. Additionally, the mitigation layer includes solid features. In at least one embodiment, mitigation layer has therein bonded solid features. In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded or otherwise connected to each other to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned external to or within the biocompatible membrane composite to provide support to and prevent distortion. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.
    Type: Grant
    Filed: May 30, 2020
    Date of Patent: May 27, 2025
    Assignees: W. L. Gore & Associates, Inc., ViaCyte, Inc.
    Inventors: Timothy M. Bruhn, Kevin D'Amour, Christopher Folk, Craig McGreevy, Laura Martinson, Scott A. Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Joseph Kakkassery
  • Publication number: 20250152324
    Abstract: Described is a multilayer cell encapsulation device and methods of assembly and uses thereof. In some examples, a multilayer cell encapsulation device can include a non-non-woven fabric (NWF) layer defining at least one chamber configured to receive cells therein, and a non-woven fabric (NWF) layer arranged external to the non-NWF layer, where the NWF layer and the non-NWF layer are suction welded together. At least a portion of a perimeter of at least the non-NWF layer which forms an outer weld of the device comprises a plurality of spaced apart flow holes extending along the perimeter.
    Type: Application
    Filed: February 24, 2023
    Publication date: May 15, 2025
    Applicant: ViaCyte, Inc.
    Inventors: Mario Zamarripa, Craig McGreevy, Jonathan Valdez, Christopher Folk, Michael Scott, Vahid Hamzeinejad, Qiang Zhang
  • Patent number: 12296125
    Abstract: Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: May 13, 2025
    Assignee: ViaCyte, Inc.
    Inventors: Vincent So, Laura Martinson, Chad Green, Michael Scott, Mario Zamarripa
  • Patent number: 12234477
    Abstract: The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 25, 2025
    Assignee: ViaCyte, Inc.
    Inventor: Thomas C Schulz
  • Publication number: 20250032672
    Abstract: Disclosed are cell encapsulation devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. In some examples, a cell encapsulation can comprise a lumen configured to receive cells therein, a cell-excluding membrane, where the lumen is internal to the cell-excluding membrane, and a non-woven fabric layer external to the cell-excluding membrane, where the non-woven fabric layer and the cell-excluding membrane comprise perforations. The device can further comprise a woven mesh external to the non-woven fabric layer, where the non-woven fabric layer provides protection to the cell-excluding membrane from direct contact with the woven mesh.
    Type: Application
    Filed: October 10, 2024
    Publication date: January 30, 2025
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
  • Patent number: 12173323
    Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.
    Type: Grant
    Filed: January 11, 2022
    Date of Patent: December 24, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
  • Publication number: 20240409900
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Application
    Filed: January 18, 2024
    Publication date: December 12, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Patent number: 12144908
    Abstract: Disclosed are cell encapsulation devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. In some examples, a cell encapsulation can comprise a lumen configured to receive cells therein, a cell-excluding membrane, where the lumen is internal to the cell-excluding membrane, and a non-woven fabric layer external to the cell-excluding membrane, where the non-woven fabric layer and the cell-excluding membrane comprise perforations. The device can further comprise a woven mesh external to the non-woven fabric layer, where the non-woven fabric layer provides protection to the cell-excluding membrane from direct contact with the woven mesh.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: November 19, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
  • Publication number: 20240299462
    Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
    Type: Application
    Filed: May 13, 2024
    Publication date: September 12, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Kevin Allen D'Amour
  • Publication number: 20240245481
    Abstract: Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.
    Type: Application
    Filed: February 7, 2024
    Publication date: July 25, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Vincent So, Erik Olson, Michael Scott, Chad Green, Giacomo Strollo, Gustavo Prado, Craig McGreevy, Laura Martinson, Donald Koenig
  • Publication number: 20240218324
    Abstract: The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.
    Type: Application
    Filed: September 26, 2023
    Publication date: July 4, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Allan J. Robins, Thomas C. Schulz
  • Publication number: 20240165212
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Application
    Filed: September 21, 2023
    Publication date: May 23, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 11925488
    Abstract: Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: March 12, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Vincent So, Erik Olson, Michael Scott, Chad Green, Giacomo Strollo, Gustavo Prado, Craig McGreevy, Laura Martinson, Donald Koenig
  • Patent number: 11920154
    Abstract: The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: March 5, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Allan J Robins, Thomas C Schulz
  • Patent number: 11905530
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 20, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz